- Home
- XBIT vs ALXO Comparison
XBIT vs ALXO Comparison
Compare XBIT & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XBIT | ALXO |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.3M | 68.3M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | XBIT | ALXO |
|---|---|---|
| Price | $2.31 | $2.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 23.4K | ★ 717.0K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.09 | $0.41 |
| 52 Week High | $3.62 | $2.66 |
Technical Indicators
Market Signals| Indicator | XBIT | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 44.93 | 50.48 |
| Support Level | $2.15 | $2.01 |
| Resistance Level | $2.69 | $2.31 |
| Average True Range (ATR) | 0.10 | 0.18 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 37.93 | 22.31 |
Price Performance
Historical ComparisonAbout XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.